CLAIMS

1. A compound of the formula (1) :



(1)

wherein:

a)

- Q is a saturated 1 to 4 carbon atom chain substituted with a $(C_1$-$C_4)$alkyl;
- R_1 is hydrogen or $(C_1$-$C_4)$alkyl;
- R_2 is hydrogen, $(C_1$-$C_4)$alkyl or benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy$(C_1$-$C_6)$alkyl, $(C_1$-$C_4)$alkyl, $(C_1$-$C_6)$alkoxy, halo, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or $(C_1$-$C_6)$alkyl optionally substituted by a hydroxy;
- A is

  - C_3-C_6 cycloalkyl, optionally substituted with hydroxy or $(C_1$-$C_4)$alkyl;

  - 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N, said heterocyclyl being optionally substituted with $(C_1$-$C_4)$alkyl or NR_9R_{10}; or



  wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, hydroxy$(C_1$-$C_6)$alkyl, thio$(C_1$-$C_6)$alkyl, halo or trifluoromethyl; and

  R_9 and R_{10} are identical or different and are hydrogen or $(C_1$-$C_4)$alkyl; or

b)

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a (C_1-C_4)alkyl;
- R_1 is hydrogen or (C_1-C_4)alkyl;
- R_2 is benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy(C_1-C_6)alkyl, (C_1-C_4)alkyl, (C_1-C_6)alkoxy, halo, O-CF_3, NR_9SO_2(C_1-C_4)alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or (C_1-C_6)alkyl optionally substituted by a hydroxy;
- A is

  - C_3-C_6 cycloalkyl, optionally substituted with hydroxy or (C_1-C_4)alkyl;

  - 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N, said heterocyclyl being optionally substituted with (C_1-C_4)alkyl or NR_9R_{10}; or



,

wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, NR_9SO_2(C_1-C_4)alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; and

R_9 and R_{10} are identical or different and are hydrogen or (C_1-C_4)alkyl; or

c)

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a (C_1-C_4)alkyl;
- R_1 is hydrogen or (C_1-C_4)alkyl;
- R_2 is hydrogen, (C_1-C_4)alkyl or benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy(C_1-C_6)alkyl, (C_1-C_4)alkyl, (C_1-C_6)alkoxy, halo, O-CF_3, NR_9SO_2(C_1-C_4)alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or (C_1-C_6)alkyl optionally substituted by a hydroxy;
- A is

  - C_3-C_6 cycloalkyl, optionally substituted with hydroxy or C_1-C_4)alkyl;

- 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N, said heterocyclyl being optionally substituted with $(C_1\text{-}C_4)$alkyl or NR_9R_{10}; or



,

wherein one of R_4, R_5, R_6, R_7 and R_8 is O-CF_3, $NR_9SO_2(C_1\text{-}C_4)$alkyl, $SO_2NR_9R_{10}$ or NR_9R_{10} and the remaining R_4, R_5, R_6, R_7 or R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1\text{-}C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, hydroxy$(C_1\text{-}C_6)$alkyl, thio$(C_1\text{-}C_6)$alkyl, halo or trifluoromethyl;

R_9 and R_{10} are the same or different and are H or $(C_1\text{-}C_4)$alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein:

- Q is a saturated 1 to 4 carbon atom chain substituted with a $(C_1\text{-}C_4)$alkyl;
- R_1 is hydrogen or $(C_1\text{-}C_4)$alkyl;
- R_2 is hydrogen, $(C_1\text{-}C_4)$alkyl or benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_6)$alkoxy, halo, O-CF_3, $NR_9SO_2(C_1\text{-}C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or $(C_1\text{-}C_6)$alkyl optionally substituted by a hydroxy;
- A is

  - $C_3\text{-}C_6$ cycloalkyl, optionally substituted with hydroxy or $(C_1\text{-}C_4)$alkyl;

  - 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N, said heterocyclyl being optionally substituted with $(C_1\text{-}C_4)$alkyl or NR_9R_{10}; or



,

wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; and

R_9 and R_{10} are the same or different and are H or (C_1-C_4)alkyl;

or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1 wherein:

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a (C_1-C_4)alkyl;
- R_1 is hydrogen or (C_1-C_4)alkyl;
- R_2 is benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy(C_1-C_6)alkyl, (C_1-C_4)alkyl, (C_1-C_6)alkoxy, halo, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or (C_1-C_6)alkyl optionally substituted by a hydroxy;
- A is
  - C_3-C_6 cycloalkyl, optionally substituted with hydroxy or (C_1-C_4)alkyl;
  - 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, Sand N, said heterocyclyl being optionally substituted with (C_1-C_4)alkyl or NR_9R_{10}; or



,

wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; and

R_9 and R_{10} are the same or different and are H or (C_1-C_4)alkyl;

or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 wherein:

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a (C_1-C_4)alkyl;
- R_1 is hydrogen or (C_1-C_4)alkyl;
- R_2 is hydrogen, (C_1-C_4)alkyl or benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy(C_1-C_6)alkyl, (C_1-C_4)alkyl, (C_1-C_6)alkoxy, halo, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10};
- R_3 is hydrogen or (C_1-C_6)alkyl optionally substituted by a hydroxy;
- A is

  - C_3-C_6 cycloalkyl, optionally substituted with hydroxy or (C_1-C_4)alkyl;

  - 5- to 10-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N, said heterocyclyl being optionally substituted with (C_1-C_4)alkyl or NR_9R_{10}; or



wherein one of R_4, R_5, R_6, R_7 and R_8 is O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$ or NR_9R_{10} and the remaining R_4, R_5, R_6, R_7 or R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; and

R_9 and R_{10} are the same or different and are H or (C_1-C_4)alkyl;

or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1, 2, 3 or 4 wherein R_1 is methyl or ethyl.

6. A compound of claim 5 wherein R_1 is methyl.

7. A compound of claim 1, 2 or 4 wherein R_2 is H, methyl, ethyl or benzyl.

8. A compound of claim 1, 2, 3 or 4 wherein R_3 is H or methyl.

9. A compound of claim 1, 3 or 4 wherein Q is $-CH_2-$, $-CH_2-CH_2-$ or $-CH(CH_3)-$.

10. A compound of claim 1 or 2 wherein Q is $-CH_2-$.

11. A compound of claim 1, 2 or 3 wherein A is C_3-C_6 cycloalkyl; 5 or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms selected from O, S and N; or



wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $SO_2NR_9R_{10}$, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl.

12. A compound of claim 1 or 2 wherein:

- Q is a saturated 1 to 4 carbon atom chain substituted with a (C_1-C_4)alkyl;
- R_1 is (C_1-C_4)alkyl;
- R_2 is hydrogen, (C_1-C_4)alkyl or benzyl;
- R_3 is hydrogen or (C_1-C_6)alkyl; and
- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N; or



,

wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

13. A compound of claim 1 or 3 wherein:

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a (C_1-C_4)alkyl;
- R_1 is hydrogen or (C_1-C_4)alkyl;
- R_2 is benzyl;
- R_3 is hydrogen or (C_1-C_6)alkyl; and
- A is

  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N; or



,

wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, thio(C_1-C_6)alkyl, halo or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

14. A compound of claim 1 or 4 wherein:

- Q is a single bond or a saturated 1 to 4 carbon atom chain optionally substituted with a $(C_1$-$C_4)$alkyl;
- R_1 is hydrogen or $(C_1$-$C_4)$alkyl;
- R_2 is hydrogen, $(C_1$-$C_4)$alkyl or benzyl;
- R_3 is hydrogen or $(C_1$-$C_6)$alkyl; and
- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing from 1 to 3 heteroatoms, identical or different, selected from O, S and N; or



,

wherein one of R_4, R_5, R_6, R_7 and R_8 is O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$ or NR_9R_{10} and the remaining R_4, R_5, R_6, R_7 or R_8 are each independently hydrogen, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, NR_9R_{10}, benzyloxy, hydroxy, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, hydroxy$(C_1$-$C_6)$alkyl, thio$(C_1$-$C_6)$alkyl, halo or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

15. A compound of claim 1 or 2 wherein:

- Q is -$CH(CH_3)$-;
- R_1 is methyl or ethyl;
- R_2 is hydrogen, methyl, ethyl or benzyl;
- R_3 is hydrogen or methyl; and
- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S and N; or



wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $SO_2NR_9R_{10}$, benzyloxy, hydroxy, methyl, methoxy, ethoxy, thiomethyl, halo or trifluoromethyl.

16. A compound of claim 15 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

17. A compound of claim 15 wherein A is pyridyl or thiazolyl.

18. A compound of claim 1 or 3 wherein:

- Q is -CH_2-, -CH_2-CH_2- or -$CH(CH_3)$-;
- R_1 is methyl or ethyl;
- R_2 is benzyl;
- R_3 is hydrogen or methyl; and
- A is

  - C_3-C_6 cycloalkyl;

  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S and N; or



wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $SO_2NR_9R_{10}$, benzyloxy, hydroxy, methyl, methoxy, ethoxy, thiomethyl, halo or trifluoromethyl.

19. A compound of claim 18 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

20. A compound of claim 18 wherein A is pyridyl or thiazolyl.

21. A compound of claim 1 or 4 wherein:

- Q is $-CH_2-$, $-CH_2-CH_2-$ or $-CH(CH_3)-$;
- R_1 is methyl or ethyl;
- R_2 is hydrogen, methyl, ethyl or benzyl;
- R_3 is hydrogen or methyl; and
- A is
- - C_3-C_6 cycloalkyl;

  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S and N; or



wherein one of R_4, R_5, R_6, R_7 and R_8 is O-CF_3 or $SO_2NR_9R_{10}$ and the remaining R_4, R_5, R_6, R_7 or R_8 are each independently hydrogen, O-CF_3, $SO_2NR_9R_{10}$, benzyloxy, hydroxy, methyl, methoxy, ethoxy, thiomethyl, halo or trifluoromethyl.

22. A compound of claim 21 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

23. A compound of claim 21 wherein A is pyridyl or thiazolyl.

24. A compound of claim 1 or 2 wherein:

- Q is $-CH(CH_3)-$;
- R_1 is methyl or ethyl;
- R_2 is hydrogen, methyl, ethyl or benzyl;
- R_3 is hydrogen; and

- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S and N; or



wherein R_4, R_5, R_6, R_7 and R_8 are each independently selected from the group consisting of hydrogen, O-CF_3, $SO_2NR_9R_{10}$ or methoxy.

25. A compound of claim 24 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

26. A compound of claim 24 wherein A is pyridyl or thiazolyl.

27. A compound of claim 1 or 3 wherein:

- Q is -CH_2- or -$CH(CH_3)$-;
- R_1 is methyl or ethyl;
- R_2 is benzyl;
- R_3 is hydrogen; and
- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S and N; or



wherein R_4, R_5, R_6, R_7 and R_8 are each independently hydrogen, O-CF_3, $SO_2NR_9R_{10}$ or methoxy.

28. A compound of claim 27 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

29. A compound of claim 27 wherein A is pyridyl or thiazolyl.

30. A compound of claim 1 or 4 wherein:

- Q is $-CH_2-$ or $-CH(CH_3)-$;
- R_1 is methyl or ethyl;
- R_2 is hydrogen, methyl, ethyl or benzyl;
- R_3 is hydrogen; and
- A is
  - C_3-C_6 cycloalkyl;
  - 5- or 6-membered aromatic heterocyclyl containing 1 or 2 heteroatoms, identical or different, selected from S or N; or



,

wherein one of R_4, R_5, R_6, R_7 and R_8 is $O-CF_3$ or $SO_2NR_9R_{10}$ and the remaining R_4, R_5, R_6, R_7 or R_8 are each independently hydrogen, $O-CF_3$, $SO_2NR_9R_{10}$ or methoxy.

31. A compound of claim 30 wherein A is cyclopropyl, cyclopentyl or cyclohexyl.

32. A compound of claim 30 wherein A is pyridyl or thiazolyl.

33. 5-[(2R)-2-({(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl phenyl)ethyl} amino)propyl}-N-(2-trifluoromethoxybenzyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl} amino)propyl}-N-[(1S)-1-phenylethyl]-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(3-trifluoromethoxyphenylethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(pyridin-2-ylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(cyclopropylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-[(1R)-1-phenylethyl]-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(thiazol-2-ylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(cyclobutylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(cyclopentylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(cyclohexylmethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(4-methylsulfamoylbenzyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(4-sulfamoylbenzyl)-1H-indole-2-carboxamide;

1-benzyl-5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-(2-methoxybenzyl)-1H-indole-2-carboxamide;

1-benzyl-5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl}amino)propyl}-N-[(1R)-1-phenylethyl]-1H-indole-2-carboxamide;

1-ethyl-5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl) ethyl}amino)propyl}-N-[(1R)-2-phenylethyl)-1H-indole-2-carboxamide;

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl} amino)propyl}-N-[(1R)-1-phenylethyl)-1-methyl-1H-indole-2-carboxamide;

1-benzyl-5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl) ethyl}amino)propyl}-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide; or

5-[(2R)-2-({(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl} amino)butyl}-N-[(1R)-1-phenylethyl]-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

34. A process for preparing a compound of claim 1 comprising coupling an acid of formula (2):



(2)

with an amine of formula (3) :



(3)

wherein R_1, R_2, R_3, Q and A are as defined in claim 1.

35. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically innocuous excipient or additive.

36. A method of treating a disease, disorder or condition mediated by the β2 receptor in a mammal, said method comprising administering a compound of claim 1, 2, 3 or 4 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of claim 1, 2, 3 or 4 or a pharmaceutically acceptable salt thereof and a pharmaceutically innocuous excipient or additive.

37. A method of claim 36 wherein said disease, disorder or condition is asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, obstructive or inflammatory airways diseases, pneumoconiosis, bronchitis, bronchiectasis, central nervous system disorders, premature labor, congestive heart failure, depression, inflammatory skin diseases, allergic skin diseases, psoriasis, proliferative skin diseases, glaucoma, gastric ulceration or peptic ulceration.

38. A method of claim 37 wherein said asthma is atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, non-atopic asthma, bronchitic asthma, emphysematous asthma, exercise-induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma, non-allergic asthma, incipient asthma, wheezy infant syndrome or bronchiolytis.

39. The method of claim 38 wherein said infective asthma is caused by bacterial, fungal, protozoal or viral infection.

40. The method of claim 37 wherein said obstructive or inflammatory airways disease is chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD associated with chronic bronchitis, COPD associated with pulmonary emphysema, COPD associated with dyspnea, COPD characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent

to other drug therapy or airways disease associated with pulmonary hypertension.

41. The method of claim 37 wherein said pneumoconiosis is aluminosis, bauxite workers' disease, anthracosis, miners' asthma, asbestosis, steam-fitters' asthma, chalicosis, flint disease, ptilosis caused by inhaling the dust from ostrich feathers, siderosis caused by the inhalation of iron particles, silicosis, grinders' disease, byssinosis, cotton-dust asthma or talc pneumoconiosis.

42. The method of claim 37 wherein said bronchitis is acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcus bronchitis, streptococcal bronchitis or vesicular bronchitis.

43. The method of claim 37 wherein said bronchiectasis is cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis or follicular bronchiectasis.

44. The method of claim 37 wherein said central nervous system disorder is depression, Alzheimers disease, Parkinson's disease, learning impairment, memory impairment, tardive dyskinesia, drug dependence, arteriosclerotic dementia, dementia associated with Huntington's chorea, Wilson's disease, paralysis agitans or thalamic atrophies.

45. The method of claim 36 wherein said mammal is a human.

46. The method of claim 37 wherein said mammal is a human.

47. A compound of formula (2):



(2)

wherein R_1 is hydrogen or $(C_1$-$C_4)$alkyl; R_2 is benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy$(C_1$-$C_6)$alkyl, $(C_1$-$C_4)$alkyl, $(C_1$-$C_6)$alkoxy, halo, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10}; and R_9 and R_{10} are identical or different and are hydrogen or $(C_1$-$C_4)$alkyl.

48. A compound of formula (4):



(4)

wherein R_1 is hydrogen or $(C_1$-$C_4)$alkyl; R_2 is benzyl optionally substituted with 1, 2 or 3 hydroxy, hydroxy$(C_1$-$C_6)$alkyl, $(C_1$-$C_4)$alkyl, $(C_1$-$C_6)$alkoxy, halo, O-CF_3, $NR_9SO_2(C_1$-$C_4)$alkyl, $SO_2NR_9R_{10}$, trifluoromethyl or NR_9R_{10}; and R_9 and R_{10} are identical or different and are hydrogen or $(C_1$-$C_4)$alkyl.

49. A compound of claim 47 or 48 wherein R_2 is benzyl.